



ajanta pharma limited

Ajanta House,
Charkop, Kandivli West,
Mumbai 400 067
India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

25th January 2019

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

Subject: Notice of the meeting of Board of Directors of Ajanta Pharma Limited (the “Company”) to consider buyback of equity shares having face value of Rs.2 (Rupees Two Only) each (“Equity Shares”)

Dear Sir/Madam,

Ref.: Prior intimation pursuant to Regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”)

This is with reference to our letter dated 21st January 2019, informing you about the Board meeting of the Company scheduled to be held on Wednesday, 30th January 2019 (“**Board Meeting**”), to consider, inter alia the unaudited financial results for the third quarter ended 31st December 2018.

Pursuant to Regulation 29(1)(b) of LODR Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider a proposal for buy-back of the Equity Shares of the Company including matters related & incidental thereto (“**Buyback**”) and any other matter as the Board of Directors of the Company may decide during the course of the meeting.

You are requested to please take a note of the same.

Thanking you,

Yours faithfully,
For Ajanta Pharma Limited


GAURANG SHAH
AVP – Legal & Company Secretary